{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T18:30:52Z","timestamp":1788546652247,"version":"build-2803163510"},"reference-count":24,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T00:00:00Z","timestamp":1751500800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Lung adenocarcinoma is a common malignancy in clinical practice, but the coexistence of lung and gastric adenocarcinomas in a single patient is rare. This report presents the case of a 70-year-old male with a history of smoking for over 30 years, diagnosed with both lung adenocarcinoma and gastric adenocarcinoma through lung biopsy and gastroscopy. Following comprehensive evaluations and exclusion of treatment contraindications, the patient underwent a therapeutic regimen comprising Sintilimab combined with nab-paclitaxel and cisplatin. Genetic testing of the lung cancer tissue identified mutations in the epidermal growth factor receptor (<jats:italic>EGFR<\/jats:italic>) gene, specifically p.L858R in exon 21 and p.T790M in exon 20. Consequently, the patient was prescribed Almonertinib at a dose of 110 mg\/day to target these mutations. Approximately 72 h after initiating Almonertinib, the patient developed dizziness and nausea, accompanied by hypotension (blood pressure: 80\/58 mmHg). Echocardiographic findings and NT-proBNP levels indicated no structural cardiac abnormalities or significant dysfunction. Almonertinib was discontinued, but subsequent attempts to reintroduce the drug consistently resulted in hypotension. After cardiology specialists evaluation, the hypotension was attributed to Almonertinib, prompting its permanent discontinuation. The treatment was adjusted to replace Almonertinib with Furmonertinib at a dose of 80 mg\/day for lung adenocarcinoma, while maintaining the initial immunotherapy and chemotherapy regimen for gastric adenocarcinoma. Following these adjustments, the patient experienced no recurrence of hypotension. This case report reviews the literature to explore potential mechanisms of Almonertinib-induced hypotension and offers insights into the prevention, diagnosis, and management of similar adverse events in clinical practice.<\/jats:p>","DOI":"10.3389\/fonc.2025.1566768","type":"journal-article","created":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T04:10:35Z","timestamp":1751515835000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Severe hypotension induced by Almonertinib: a case report with literature review and clinical insights"],"prefix":"10.3389","volume":"15","author":[{"given":"Haiyu","family":"Niu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feixue","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaochun","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiaoying","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yating","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benxin","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanwen","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,7,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"170070","DOI":"10.1098\/rsob.170070","article-title":"Progress and prospects of early detection in lung cancer","volume":"7","author":"Blandin Knight","year":"2017","journal-title":"Open Biol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"8661","DOI":"10.3390\/ijms22168661","article-title":"Current and future development in lung cancer diagnosis","volume":"22","author":"Nooreldeen","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B3","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41572-024-00551-9","article-title":"Non-small-cell lung cancer","volume":"10","author":"Hendriks","year":"2024","journal-title":"Nat Rev Dis Primers"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.11.003","article-title":"The 2021 WHO classification of lung tumors: impact of advances since 2015","volume":"17","author":"Nicholson","year":"2022","journal-title":"J Thorac Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e318206a221","article-title":"International association for the study of lung cancer\/American thoracic society\/European respiratory society international multidisciplinary classification of lung adenocarcinoma","volume":"6","author":"Travis","year":"2011","journal-title":"J Thorac Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1408440","article-title":"First-line crizotinib versus chemotherapy in ALK-positive lung cancer","volume":"371","author":"Solomon","year":"2014","journal-title":"New Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2014.08.003","article-title":"Is the ABCB1 gene associated with the increased risk of gastric cancer development?\u2013preliminary research","volume":"210","author":"Zebrowska","year":"2014","journal-title":"Pathol Res Pract"},{"key":"B8","doi-asserted-by":"publisher","first-page":"188615","DOI":"10.1016\/j.bbcan.2021.188615","article-title":"Advances in clinical immunotherapy for gastric cancer","volume":"1876","author":"Li","year":"2021","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"B9","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.3390\/ijerph20032149","article-title":"Early gastric cancer: update on prevention, diagnosis and treatment","volume":"20","author":"Conti","year":"2023","journal-title":"Int J Environ Res Public Health"},{"key":"B10","doi-asserted-by":"publisher","first-page":"867","DOI":"10.21037\/atm-21-1606","article-title":"Absorption, metabolism, excretion, and safety of [(14)C]almonertinib in healthy Chinese subjects","volume":"9","author":"Zhou","year":"2021","journal-title":"Ann Trans Med"},{"key":"B11","doi-asserted-by":"publisher","first-page":"12577","DOI":"10.3390\/ijms241612577","article-title":"Tools for etiologic diagnosis of drug-induced allergic conditions","volume":"24","author":"Rodriguez-Perez","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA: Cancer J Clin"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.33691","article-title":"Comparing gefitinib and traditional chemotherapy for better survival in patients with non-small cell lung cancer: A systematic review","volume":"15","author":"Kanagalingam","year":"2023","journal-title":"Cureus"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2021.5168","article-title":"Overall survival in stage IV EGFR mutation\u2212positive NSCLC: Comparing first\u2212, second\u2212 and third\u2212generation EGFR\u2212TKIs (Review)","volume":"58","author":"Vaid","year":"2021","journal-title":"Int J Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.4c01405","article-title":"Discovery of a novel mutant-selective epidermal growth factor receptor inhibitor using an in silico enabled drug discovery platform","volume":"67","author":"Igawa","year":"2024","journal-title":"J medicinal Chem"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-021-00794-6","article-title":"Osimertinib versus comparator EGFR TKI as first-line treatment for EGFR-mutated advanced NSCLC: FLAURA China, A randomized study","volume":"16","author":"Cheng","year":"2021","journal-title":"Targeted Oncol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s12943-018-0777-1","article-title":"Management of acquired resistance to EGFR TKI-targeted therapy in advanced non-small cell lung cancer","volume":"17","author":"Wu","year":"2018","journal-title":"Mol Cancer"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2020.09.001","article-title":"Safety, efficacy, and pharmacokinetics of almonertinib (HS-10296) in pretreated patients with EGFR-mutated advanced NSCLC: A multicenter, open-label, phase 1 trial","volume":"15","author":"Yang","year":"2020","journal-title":"J Thorac Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02641","article-title":"AENEAS: A randomized phase III trial of aumolertinib versus gefitinib as first-line therapy for locally advanced or metastaticNon-small-cell lung cancer with EGFR exon 19 deletion or L858R mutations","volume":"40","author":"Lu","year":"2022","journal-title":"J Clin Oncol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1186\/1752-1947-6-266","article-title":"Synchronous lung and gastric cancers successfully treated with carboplatin and pemetrexed: a case report","volume":"6","author":"Sato","year":"2012","journal-title":"J Med Case Rep"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1404692","article-title":"Advancements in understanding cardiotoxicity of EGFR- TKIs in non-small cell lung cancer treatment and beyond","volume":"15","author":"Li","year":"2024","journal-title":"Front Pharmacol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1097\/CAD.0000000000001244","article-title":"Hypotension from afatinib in epidermal growth factor receptor-mutated non-small cell lung cancer: a case report and literature review","volume":"33","author":"Tang","year":"2022","journal-title":"Anti-cancer Drugs"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1089184","article-title":"Case report: Savolitinib induced severe adverse reactions resembling septic shock in an HIV-1-positive patient with advanced non-small cell lung cancer","volume":"14","author":"Xiong","year":"2023","journal-title":"Front Pharmacol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.3390\/biomedicines12071412","article-title":"Potential utility of a 4th-generation EGFR-TKI and exploration of resistance mechanisms-an in vitro study","volume":"12","author":"Fukuda","year":"2024","journal-title":"Biomedicines"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1566768\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T04:10:36Z","timestamp":1751515836000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1566768\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,3]]},"references-count":24,"alternative-id":["10.3389\/fonc.2025.1566768"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1566768","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,3]]},"article-number":"1566768"}}